A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Open to people ages 40 years and up

• Have a diagnosis of type 2 diabetes
• Have confirmed atherosclerotic cardiovascular disease
• HbA1c ≥7.0% to ≤10.5%
• Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)

• Have had a major cardiovascular event within the last 60 days
• Have type 1 diabetes mellitus
• Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
• Have a history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
• Currently planning a coronary, carotid, or peripheral artery revascularization
• Have a history of pancreatitis
• Have a history of ketoacidosis or hyperosmolar state/coma
• Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect gastrointestinal (GI) motility
• Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)